Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries

• Autoři: WIDIMSKÝ Petr; WIJNS William; FAJADET Jean; DE BELDER Mark; KNOT Jiří; AABERGER Lars; ANDRIKOPOULOS George; BAZ Jose Antonio; BETRIU Amadeo; CLAEYS Marc; DANCHIN Nicolas; DJAMBAZOV Slaveyko; ERNE Paul; HARTIKAINEN Juha; HUBER Kurt; KALA Petr; KLINCEVA Milka; KRISTENSEN Steen Dalby; LUDMAN Peter; FERRE Josephina Mauri; MERKELY Bella; MILICIC Davor; MORAIS Joao; NOC Marko; OPOLSKI Grzegorz; OSTOJIC Miodrag; RADOVANOVIC Dragana; DE SERVI Stefano; STENESTRAND Ulf; STUDENCAN Martin; TUBARO Marco; VASILJEVIC Zorana; WEIDINGER Franz; WITKOWSKI Adam; ZEYMER Uwe
• Rok publikování: 2010
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: European Heart Journal
• Fakulta / Pracoviště MU: Lékařská fakulta
• Doi: http://dx.doi.org/10.1093/eurheartj/ehp492
• Obor: Kardiovaskulární nemoci včetně kardiochirurgie
• Klíčová slova: Acute myocardial infarction; Reperfusion therapy; Thrombolysis; Primary angioplasty; Europe; Mortality; Incidence
• Popis: Patient access to reperfusion therapy and the use of primary percutaneous coronary intervention (p-PCI) or thrombolysis (TL) varies considerably between European countries. The aim of this study was to obtain a realistic contemporary picture of how patients with ST elevation myocardial infarction (STEMI) are treated in different European countries. Methods and results The chairpersons of the national working groups/societies of interventional cardiology in European countries and and results selected experts known to be involved in the national registries joined the writing group upon invitation. Data were collected about the country and any existing national STEMI or PCI registries, about STEMI epidemiology, and treatment in each given country and about PCI and p-PCI centres and procedures in each country. Results from the national and/or regional registries in 30 countries were included in this analysis. The annual incidence of hospital admission for any acute myocardial infarction (AMI) varied between 90-312/100 thousand/year, the incidence of STEMI alone ranging from 44 to 142. Primary PCI was the dominant reperfusion strategy in 16 countries and TL in 8 countries. The use of a p-PCI strategy varied between 5 and 92% (of all STEMI patients) and the use of TL between 0 and 55%. Any reperfusion treatment (p-PCI or TL) was used in 37-93% of STEMI patients. Significantly less reperfusion therapy was used in those countries where TL was the dominant strategy. The number of p-PCI procedures per million per year varied among countries between 20 and 970. The mean population served by a single p-PCI centre varied between 0.3 and 7.4 million inhabitants. In those countries offering p-PCI services to the majority of their STEMI patients, this population varied between 0.3 and 1.1 million per centre. In-hospital mortality of all consecutive STEMI patients varied between 4.2 and 13.5%, for patients treated by TL between 3.5 and 14% and for patients treated by p-PCI between 2.7 and 8%. The time reported from symptom onset to the first medical contact (FMC) varied between 60 and 210 min, FMC-needle time for TL between 30 and 110 min, and FMC-balloon time for p-PCI between 60 and 177 min. Conclusion Most North, West, and Central European countries used p-PCI for the majority of their STEMI patients. The lack of organized p-PCI networks was associated with fewer patients overall receiving some form of reperfusion therapy.